Scientific Sessions

Recent years have witnessed remarkable progress in the understanding, diagnosis, and treatment of viral infections. Advancements in genomic sequencing have played a pivotal role in identifying new and re-emerging viruses, allowing for early detection and more effective outbreak responses. Technologies such as CRISPR-based diagnostics and next-generation sequencing (NGS) have enabled real-time surveillance of viral mutations, particularly important for rapidly evolving pathogens like influenza, HIV, and coronaviruses. Moreover, the development of mRNA vaccine platforms, first widely used during the COVID-19 pandemic, has revolutionized vaccine science, offering a faster, adaptable, and scalable approach to vaccine production for various viral diseases.

Parallel to these innovations, antiviral drug development has seen significant breakthroughs. Novel broad-spectrum antivirals and targeted therapies have been introduced, improving outcomes for diseases such as hepatitis C, HIV/AIDS, and herpesvirus infections. Immunotherapeutic approaches, including monoclonal antibodies and T-cell-based therapies, are also showing promise in treating chronic and severe viral infections. In addition, advances in nanotechnology and drug delivery systems are enhancing the effectiveness and precision of antiviral treatments. Public health strategies have also evolved, incorporating digital tools for contact tracing, predictive modeling, and information dissemination, thus strengthening global preparedness and response capabilities. As the scientific community continues to uncover complex virus-host interactions and immune responses, these insights pave the way for more personalized and effective interventions in the fight against viral infections.